Antigen News and Research RSS Feed - Antigen News and Research

New study reports significant increase in new metastatic prostate cancer cases

New study reports significant increase in new metastatic prostate cancer cases

The number of new cases of metastatic prostate cancer climbed 72 percent in the past decade from 2004 to 2013, reports a new Northwestern Medicine study. [More]
Researchers develop first protective vaccine against insidious STI

Researchers develop first protective vaccine against insidious STI

The first steps towards developing a vaccine against an insidious sexual transmitted infection (STI) have been accomplished by researchers at McMaster University. [More]
Soligenix announces encouraging preliminary results of heat stable Ebola vaccine

Soligenix announces encouraging preliminary results of heat stable Ebola vaccine

A biopharmaceutical company collaborating with Hawai'i scientists on an Ebola vaccine announced encouraging news about its vaccine today. [More]
Cancer immunotherapy could treat HIV

Cancer immunotherapy could treat HIV

A type of immunotherapy that has shown promising results against cancer could also be used against HIV, the virus that causes AIDS. [More]
New study highlights role of TANs in regulating T cell responses in patients with early-stage lung cancer

New study highlights role of TANs in regulating T cell responses in patients with early-stage lung cancer

The microenvironment of tumors is a mix of cell types, mostly comprised of inflammatory cells. White blood cells, recruited from the blood and bone marrow, represent a significant portion of these inflammatory cells and influence nearly all steps of tumor progression. [More]
Study finds evidence that PD-1 antibody may benefit men with metastatic prostate cancer

Study finds evidence that PD-1 antibody may benefit men with metastatic prostate cancer

Restoring tumor-specific immunity is a treatment strategy that works well in melanoma and lung cancer patients. Now a new study out of the OHSU Knight Cancer Institute is reviving hope that the approach also may help men with life-threatening prostate cancer. [More]
Gender matching may be beneficial to reduce risk of corneal transplant rejection and failure

Gender matching may be beneficial to reduce risk of corneal transplant rejection and failure

A study of patients undergoing corneal transplants indicates that subtle differences between men and women may lead to poorer outcomes for a woman who has received a cornea from a male donor. [More]
The Wistar Institute and partners receive HIV cure research grant to test novel immunotherapies

The Wistar Institute and partners receive HIV cure research grant to test novel immunotherapies

The Wistar Institute is pleased to announce that the National Institutes of Health has awarded a nearly $23 million Martin Delaney Collaboratories for HIV Cure Research grant to the BEAT-HIV: Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy, a consortium of top HIV researchers led by co-principal investigators Luis J. Montaner, D.V.M., D.Phil., director of the HIV-1 Immunopathogenesis Laboratory at The Wistar Institute Vaccine Center, and James L. Riley, Ph.D., research associate professor at the Perelman School of Medicine at the University of Pennsylvania. [More]
Antibodies from survivors of filovirus infection may offer protection against other filoviral diseases

Antibodies from survivors of filovirus infection may offer protection against other filoviral diseases

Ebola and Marburg filovirus disease outbreaks have typically occurred as isolated events, confined to central Africa. [More]
Two new studies find potential genetic cause and new treatment method for autoimmune diseases

Two new studies find potential genetic cause and new treatment method for autoimmune diseases

The American Autoimmune Related Diseases Association, Inc. is spotlighting two new research studies originally reported in ScienceDaily. [More]
Phase III clinical study of promising prostate cancer drug reveals surprising results

Phase III clinical study of promising prostate cancer drug reveals surprising results

A recently published international clinical Phase III trial of a promising drug for treating advanced prostate cancer ended with surprising results: the new therapeutic agent failed to achieve any significant improvement in the overall survival of patients compared with the established standard treatment. [More]
Shire’s Xiidra receives FDA approval for treating dry eye disease in adult patients

Shire’s Xiidra receives FDA approval for treating dry eye disease in adult patients

Shire plc announces that the U.S. Food and Drug Administration has approved Xiidra (lifitegrast ophthalmic solution) 5%, a twice-daily eye drop solution indicated for the treatment of the signs and symptoms of dry eye disease in adult patients. [More]
Changes in benign tissue adjacent to prostate tumors could better predict recurrence

Changes in benign tissue adjacent to prostate tumors could better predict recurrence

Changes in benign tissues next to prostate tumors may provide an early warning for patients at higher risk for biochemical recurrence after a radical prostatectomy, a study by researchers at Case Western Reserve University and Johns Hopkins Medical Institutions shows. [More]
Infant HBV vaccination prevents HCC in children, young adults

Infant HBV vaccination prevents HCC in children, young adults

Immunisation against hepatitis B virus in infants protects against the development of hepatocellular carcinoma in not only children but also young adults, a Taiwanese study finds. [More]
TDF reduces vertical HBV transmission

TDF reduces vertical HBV transmission

The mother-to-child transmission of hepatitis B virus is reduced with tenofovir disoproxil fumarate treatment during the third trimester in pregnant chronic HBV patients with a high viral load, show the findings of a trial conducted in China. [More]
Study could offer new ways to enhance cancer immunotherapy

Study could offer new ways to enhance cancer immunotherapy

When an immune T cell divides into two daughter cells, the activity of an enzyme called mTORC1, which controls protein production, splits unevenly between the progeny, producing two cells with different properties. [More]
New strategy treats fatal autoimmune disease without outward off-target effects

New strategy treats fatal autoimmune disease without outward off-target effects

In a study with potentially major implications for the future treatment of autoimmunity and related conditions, scientists from the Perelman School of Medicine at the University of Pennsylvania have found a way to remove the subset of antibody-making cells that cause an autoimmune disease, without harming the rest of the immune system. [More]
Researchers design E. coli-based transport capsule to help fight pneumococcal disease

Researchers design E. coli-based transport capsule to help fight pneumococcal disease

Most people recoil at the thought of ingesting E. coli. But what if the headline-grabbing bacteria could be used to fight disease? [More]
Scientists develop new vaccine to stimulate both innate and specific adaptive response

Scientists develop new vaccine to stimulate both innate and specific adaptive response

Though a variety of immunotherapy-based strategies are being used against cancer, they are often hindered by the inability of the immune response to enter the immunosuppressive tumor microenvironment and to effectively mount a response to cancer cells. [More]
New AAV 3.0 program to create next-generation viral vectors for better treatment of inherited diseases

New AAV 3.0 program to create next-generation viral vectors for better treatment of inherited diseases

The Perelman School of Medicine at the University of Pennsylvania has launched a new program, called AAV 3.0, to create new viral vectors to find quicker and better treatments for an array of diseases. James M. Wilson, MD, PhD, a professor of Medicine and director of the Orphan Disease Center, will lead an interdisciplinary team of over 30 scientists to create this new technology platform with support provided by the University of Pennsylvania Health System. [More]
Advertisement
Advertisement